Production of hybrid glycopeptide antibiotics in vitro and in Streptomyces toyocaensis
Background: The glycopeptide antibiotics vancomycin and teicoplanin are currently the last line of defence against some microorganisms that are resistant to many drugs. The emergence of vancomycin-resistant and teicoplanin-resistant enterococci underscores the need for more potent antibiotics. The g...
Saved in:
Published in | Chemistry & biology Vol. 4; no. 3; pp. 195 - 202 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Ltd
01.03.1997
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background: The glycopeptide antibiotics vancomycin and teicoplanin are currently the last line of defence against some microorganisms that are resistant to many drugs. The emergence of vancomycin-resistant and teicoplanin-resistant enterococci underscores the need for more potent antibiotics. The glycosylation patterns of glycopeptides and chemical modifications of the glycosyl moieties have been shown to greatly influence their antibiotic activity, and certain combinations have resulted in highly active new compounds. To explore further the production of more potent glycopeptide antibiotics, we assessed whether glycosyltransferases could be used to produce hybrid compounds that contain various combinations of sugars and peptide cores.
Results: We cloned five glycosyltransferase genes from
Amycolatopsis orientalis strains that produce vancomycin or a related glycopeptide, A82846. The
gtfB and
gtfE′ genes from
A. orientalis strains expressed in
Escherichia coli produced glucosyltransferase activities that added glucose or xylose to the vancomycin heptapeptide. The GtfE′ protein added glucose efficiently to two other heptapeptides related to teicoplanin to produce hybrid glycopeptide antibiotics. The cloned
gtfE′ gene, driven by the strong constitutive promoter
ermEp∗, was introduced into
Streptomyces toyocaensis, which produces the antibiotic A47934, a heptapeptide related to teicoplanin; recombinant organisms produced glucosyl A47934, a hybrid glycopeptide antibiotic.
Conclusions: Cloned glycosyltransferases from glycopeptide antibiotic producers can be used to produce novel hybrid antibiotics, both
in vitro and
in vivo, Because similar enzymes have differing degrees of substrate specificity, it is advantageous to characterize the substrate specificity with enzymes expressed in
E. coli prior to constructing recombinant actinomycetes for production. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
ISSN: | 1074-5521 1879-1301 |
DOI: | 10.1016/S1074-5521(97)90288-X |